<qa>  To compare TGFBR2 levels at baseline and after treatment between the group receiving bevaciIII. To compare TGFBR2 levels at baseline and after treatment between the group receiving bevacizumab alone and the group receiving bevacizumab in combination with anti-endoglin monoclonal antibody TRC105. 